PE20070352A1 - Compuestos de imidazol sustituidos como inhibidores de ksp - Google Patents

Compuestos de imidazol sustituidos como inhibidores de ksp

Info

Publication number
PE20070352A1
PE20070352A1 PE2006000968A PE2006000968A PE20070352A1 PE 20070352 A1 PE20070352 A1 PE 20070352A1 PE 2006000968 A PE2006000968 A PE 2006000968A PE 2006000968 A PE2006000968 A PE 2006000968A PE 20070352 A1 PE20070352 A1 PE 20070352A1
Authority
PE
Peru
Prior art keywords
substituted
alkyl
imidazol
aminopropyl
carboxamide
Prior art date
Application number
PE2006000968A
Other languages
English (en)
Inventor
Paul A Barsanti
Yi Xia
Kris G Mendenhall
Savithri Ramurthy
Sharadha Subramanian
Nathan M Brammeier
David Duhl
Tinya J Abrams
Paul A Renhowe
Annette O Walter
Ryan Constantine
Rustum Boyce
Megan C Phillips
Liana M Lagniton
Weibo Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070352A1 publication Critical patent/PE20070352A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 ES AMINOACILO, CARBOXILO, ALQUILO C1-C6, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ARILO C6-C14; R3 Y R4 SON CADA UNO H, OH, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON NH2, CN, HALOGENO, NITRO, ENTRE OTROS, CICLOALQUILO C3-C10 OPCIONALMENTE SUSTITUIDO CON OXO, TIOXO, NH2, ENTRE OTROS; R5 ES H, ALQUILO C1-C6 SUSTITUIDO O NO CON NH2, CN, HALOGENO, NITRO, ENTRE OTROS, ALQUENILO C2-C6 SUSTITUIDO O NO, ENTRE OTROS; R6 Y R7 SON CADA UNO CICLOALQUILO C3-C10, ARILO C6-C14, HETEROARILO, ENTRE OTROS; R8 ES L-A1; L ES ALQUILENO C1-C5 SUSTITUIDO O NO CON OH, HALO, ACILAMINO, S(O)q; q ES 1-4; A1 ES ARILO C6-C14, HETEROARILO, HETEROCICLICO, CICLOALQUILO C3-C10 SUSTITUIDO O NO CON OH, NH2, CN, TIOL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(3-AMINOPROPIL)-N-{(1R)-1-[1-BENCIL-4-(3-CLOROFENIL)-1H-IMIDAZOL-2-IL]-2-METILPROPIL}MORFOLIN-4-CARBOXAMIDA; N-(3-AMINOPROPIL)-N-{(1R)-1-[1-BENCIL-4-(3-CLOROFENIL)-1H-IMIDAZOL-2-IL]-2-METILPROPIL}PIPERIDIN-1-CARBOXAMIDA; N-(3-AMINOPROPIL)-N-[(1R)-1-(1-BENCIL-4-FENIL-1H-IMIDAZOL-2-IL)-2,2-DIMETILPROPIL]PIPERIDIN-1-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINESINA DEL HUSO (KSP) SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE PULMON, DE MAMA, DE PANCREAS, DE ESTOMAGO, LEUCEMIA MIELOIDE
PE2006000968A 2005-08-09 2006-08-09 Compuestos de imidazol sustituidos como inhibidores de ksp PE20070352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70690105P 2005-08-09 2005-08-09

Publications (1)

Publication Number Publication Date
PE20070352A1 true PE20070352A1 (es) 2007-05-30

Family

ID=37421032

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000968A PE20070352A1 (es) 2005-08-09 2006-08-09 Compuestos de imidazol sustituidos como inhibidores de ksp

Country Status (20)

Country Link
US (1) US7626040B2 (es)
EP (1) EP1912972B1 (es)
JP (1) JP4975745B2 (es)
KR (1) KR20080036611A (es)
CN (1) CN101253167A (es)
AR (1) AR056025A1 (es)
AT (1) ATE526324T1 (es)
AU (1) AU2006279991B2 (es)
BR (1) BRPI0614547A2 (es)
CA (1) CA2618747A1 (es)
ES (1) ES2374449T3 (es)
GT (1) GT200600366A (es)
HK (1) HK1111995A1 (es)
MY (1) MY147188A (es)
PE (1) PE20070352A1 (es)
PL (1) PL1912972T3 (es)
PT (1) PT1912972E (es)
RU (1) RU2413721C9 (es)
TW (1) TW200800951A (es)
WO (1) WO2007021794A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
US7820646B2 (en) * 2007-01-05 2010-10-26 Novartis Vaccines And Diagnostics, Inc. Cyclized derivatives as Eg-5 inhibitors
BRPI0818605A2 (pt) 2007-10-19 2015-04-22 Schering Corp Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
US8546434B2 (en) 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
NZ720736A (en) * 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CN108025084A (zh) * 2015-06-22 2018-05-11 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc)
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc)
KR102583006B1 (ko) 2016-12-21 2023-09-27 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
SG11202012608VA (en) 2018-06-18 2021-02-25 Bayer Ag Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
CN109481436A (zh) * 2018-08-21 2019-03-19 广东医科大学 血栓素a2合成酶抑制剂奥扎格雷在制备治疗吸烟所致肺癌药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
PT1086086E (pt) * 1998-06-12 2005-02-28 Sod Conseils Rech Applic Derivados imidazolilo e sua utilizacao como ligandos de receptores da somatostatina
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) * 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
AU2001227812A1 (en) 2000-05-02 2001-11-12 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
JP2004518613A (ja) * 2000-08-01 2004-06-24 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
WO2004100873A2 (en) * 2003-05-07 2004-11-25 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004103282A2 (en) * 2003-05-15 2004-12-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2005100322A1 (en) 2004-04-14 2005-10-27 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1765789B1 (en) * 2004-06-18 2013-02-27 Novartis AG N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
AU2006279991B2 (en) 2011-09-29
AR056025A1 (es) 2007-09-12
AU2006279991A1 (en) 2007-02-22
CA2618747A1 (en) 2007-02-22
ATE526324T1 (de) 2011-10-15
PT1912972E (pt) 2012-01-06
PL1912972T3 (pl) 2012-02-29
BRPI0614547A2 (pt) 2011-03-29
KR20080036611A (ko) 2008-04-28
US20070037853A1 (en) 2007-02-15
MY147188A (en) 2012-11-14
CN101253167A (zh) 2008-08-27
RU2413721C9 (ru) 2011-05-20
HK1111995A1 (en) 2008-08-22
RU2413721C2 (ru) 2011-03-10
EP1912972B1 (en) 2011-09-28
JP4975745B2 (ja) 2012-07-11
US7626040B2 (en) 2009-12-01
TW200800951A (en) 2008-01-01
WO2007021794A1 (en) 2007-02-22
JP2009504664A (ja) 2009-02-05
RU2008108939A (ru) 2009-09-20
EP1912972A1 (en) 2008-04-23
ES2374449T3 (es) 2012-02-16
GT200600366A (es) 2007-05-10

Similar Documents

Publication Publication Date Title
PE20070352A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
PE20120546A1 (es) Inhibidores del virus de la hepatitis c
PE20110008A1 (es) Triazolopiridazinas como moduladores de quinasa
PE20220569A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos
PE20081169A1 (es) Compuestos tipo pirazol y triazol sustituidos como inhibidores de ksp
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
PE20090772A1 (es) Derivados de bencimidazol
PE20120258A1 (es) Derivados de bencimidazol-pirrolidina como inhibidores del virus de la hepatitis c
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20120533A1 (es) Inhibidores del virus de la hepatitis c
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
EA201200653A1 (ru) Гетариламинохинолины
ECSP055987A (es) Derivados de heteroarilcarbamoilbenceno
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
PE20110931A1 (es) Pirrolidin-2-onas como ligandos de hdm2
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
ATE433981T1 (de) Heterocyclische verbindungen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed